The 5th Hong Kong International Biotechnology Conference and Exhibition (BIOHK2026) will be held from 9 to 12 September 2026 at the Hong Kong Convention and Exhibition Centre. Under the theme “Kaleidoscope,” the meeting is expected to draw nearly 200 exhibitors, more than 400 international speakers and over 10,000 professional attendees from more than 40 countries and regions — a working platform that connects science, industry and capital across Asia.
More than 50 vertical forums will cover cell and gene therapy, mRNA and exosome therapies, biomanufacturing, regulatory science and cross-border access, and oncology and precision medicine.
The full agenda is available at bio-hk.com.
Panel: Cancer Therapeutics — New Era of mRNA Medicine
On Friday, 11 September, from 12:00 to 12:40 in Conference Hall 3, CATUG Biotechnology Co-Founder and CEO Aimee Wang will join the panel “Cancer Therapeutics — New Era of mRNA Medicine,” discussing clinical breakthroughs, manufacturing bottlenecks and paths to adoption for mRNA technology in oncology.
The session will be moderated by Julie Zhu, Executive Director of the FIC Program at the College of Future Technology, Peking University. Panelists include:
- Julie Zhu, Executive Director of the FIC Program, College of Future Technology, Peking University (Moderator)
- Aimee Wang, Co-Founder & CEO, CATUG Biotechnology
- Aimin Hui, Founder, Chair and CEO, EnCureGen Pharma
- JiaYee Lee, Director, Strategy and Alliance, BioNTech Australia
- Xin Liu, Director of Healthcare Fund, Hony Capital
A Clinical Inflection Point — and a Manufacturing Test
In August 2026, Moderna and Merck announced that intismeran autogene, an individualized neoantigen mRNA cancer vaccine, combined with Keytruda (pembrolizumab), met the primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS) in the Phase 3 INTerpath-001 trial in resected Stage IIB–IV melanoma. It is the first individualized mRNA cancer vaccine to report a positive late-stage readout, and the first Phase 3 study in this setting to show a clinically meaningful improvement over Keytruda alone.
The result strengthens the case that the mRNA platform can move from prophylactic vaccines into therapeutic oncology. Deal activity around siRNA/RNAi, LNP delivery and genetic-medicine platforms has stayed active. What the market is now asking for is not another proof-of-concept sequence — it is scalable, transferable manufacturing.
What BIOHK Is Likely to Focus On
The conference’s advanced-therapy track explicitly includes mRNA and exosome therapies, cell and gene therapy, and advanced biomanufacturing. For RNA pipelines, the constraint that decides whether a program reaches patients is rarely a single design choice. It is whether the full chain can run at the same time:
- Individualized neoantigen vaccines and off-the-shelf tumor vaccine paths in parallel
- Process scale-up and lot-to-lot consistency for LNP and targeted LNP systems
- Integrated plasmid–RNA–drug product CMC packages for NMPA, FDA and EMA filings
- Aseptic fill-finish, lyophilization, and global cold-chain or solid-dosage supply
- Hong Kong CMPR, Greater Bay Area trial coordination, and cross-border technology transfer
Beyond the clinical headline, stable, scalable GMP manufacturing and CMC capability is the variable that either stalls a pipeline or moves it through.
CATUG’s Role
CATUG is an RNA-LNP CRDMO with GMP operations in Suzhou and Wuhan, covering proof of concept through commercial supply. The company supports domestic and international sponsors on oncology-related mRNA programs, from mRNA synthesis and LNP development through process scale-up, aseptic fill-finish and GMP production.
On the panel, Aimee Wang will discuss how transferable process development, quality systems and supply-chain design can take mRNA medicine from scientific validation into the clinic and, eventually, commercial use.
A Cross-Border Manufacturing Footprint
Hong Kong remains a practical hub between mainland manufacturing capacity and overseas pipelines, regulators and capital. CATUG has set up an Asia-Pacific Innovation Center at Hong Kong Science Park, a business and R&D coordination office in Princeton, New Jersey, and a European business office in Basel. The Suzhou and Wuhan GMP sites are built and operated to NMPA, FDA and EMA standards, creating a delivery model of mainland manufacturing with overseas interface.
Earlier this year the team continued those conversations at BIO 2026 in San Diego and at the Asia Global Health Summit. BIOHK2026 is the Asian continuation of that sequence: putting the clinical inflection, the manufacturing reality and the cross-border path on the same table.
On-Site Discussion
Partners attending BIOHK2026 are invited to Conference Hall 3 on 11 September at 12:00 for the oncology mRNA panel. Additional forums, regulatory sessions and one-to-one meetings should be confirmed against the official BIOHK2026 agenda.
11 September · 12:00–12:40 · Conference Hall 3
Panel: Cancer Therapeutics — New Era of mRNA Medicine
Official website and full agenda: bio-hk.com